Acciones Northwest Biotherapeutics, Inc Nasdaq
Acciones
US66737P6007
Biotecnología e investigación médica
Ventas 2022 | 1,68 M 1,57 M | Ventas 2023 | 1,93 M 1,8 M | Capitalización | 822 M 767 M |
---|---|---|---|---|---|
Resultado Neto 2022 | -105 M -97,97 M | Resultado Neto 2023 | -62 M -57,85 M | VE / Ventas 2022 | 505 x |
Deuda neta 2022 | 19,29 M 18 M | Deuda neta 2023 | 43,43 M 40,53 M | VE / Ventas 2023 | 448 x |
P/E ratio 2022 |
-7,59
x | P/E ratio 2023 |
-11,7
x | Empleados | - |
Rendimiento 2022 * |
-
| Rendimiento 2023 |
-
| Flotante | 89,55 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/01/00 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 01/04/12 |
Varia. 1 de ene. | Capi. | |
---|---|---|
-1,17 % | 104 mil M | |
+2,87 % | 97,47 mil M | |
+2,13 % | 22,25 mil M | |
-14,77 % | 21,68 mil M | |
-8,79 % | 18,2 mil M | |
-39,98 % | 17,02 mil M | |
-13,21 % | 16,36 mil M | |
+8,55 % | 14,39 mil M | |
+35,75 % | 12,37 mil M |